Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR) - Wikidata - awgldk - TriplyDB

Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR)

Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR)

http://www.wikidata.org/entity/Q27653488

about

Novel bile acid therapeutics for the treatment of chronic liver diseases FXR signaling in the enterohepatic system Role of farnesoid X receptor and bile acids in alcoholic liver disease Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia.Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation.Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: insights into the antagonism of the hypolipidemic agent Z-guggulsterone.Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding.Recent advances in the development of farnesoid X receptor agonists Studies in mice, hamsters, and rats demonstrate that repression of hepatic apoA-I expression by taurocholic acid in mice is not mediated by the farnesoid-X-receptor Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasis Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice.Structural Basis for Small Molecule NDB (N-Benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) Benzamide) as a Selective Antagonist of Farnesoid X Receptor α (FXRα) in Stabilizing the Homodimerization of the Receptor.Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease.Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR.Structural Investigation for Optimization of Anthranilic Acid Derivatives as Partial FXR Agonists by in Silico Approaches.Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor Farnesoid X receptor-Acting through bile acids to treat metabolic disorders.Bile acid receptors in non-alcoholic fatty liver disease.Farnesoid X receptor modulators: a patent review.Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators.Bile acid receptors as targets for drug development.Characterizing ligands for farnesoid X receptor--available in vitro test systems for farnesoid X receptor modulator development.Role of farnesoid X receptor in inflammation and resolution.Combining self- and cross-docking as benchmark tools: the performance of DockBench in the D3R Grand Challenge 2.FXR Agonists: From Bench to Bedside, a Guide for Clinicians.Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice Simultaneous diastereo- and enantioseparation of farnesoid X receptor (FXR) agonists with a quinine carbamate-based chiral stationary phase.Bile acids at the cross-roads of gut microbiome-host cardiometabolic interactions.Using physics-based pose predictions and free energy perturbation calculations to predict binding poses and relative binding affinities for FXR ligands in the D3R Grand Challenge 2.Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening.Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR).Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening.Cholestasis-induced bile acid elevates estrogen level via farnesoid X receptor-mediated suppression of the estrogen sulfotransferase SULT1E1 Structural insights into the heterodimeric complex of the nuclear receptors FXR and RXR Bile acid signaling and bariatric surgery Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking

P2860

Q26748613-BDEE4D31-FB4F-44FA-BBD2-92B42AD81EA2 Q27014753-3B74111F-8A1B-44CE-A1E0-D13C5B5C25B4 Q28086898-020B0091-2DA0-4E36-8217-3797CFDE24DF Q28253815-1FBBF3BB-C94D-4537-8D07-D3015AE67F15 Q33661459-EC91C2AB-2F40-43EF-A3EC-6F1736AF5575 Q34054283-3C65BE5C-B1AF-4D68-8645-89BEFBA09248 Q34065876-6E482944-4052-4037-8B90-9BD3A5D18ED4 Q34249416-9ACC640F-EE6C-43BD-8568-263873F27298 Q34464043-BA5540A2-EDE1-4AB0-8887-C96C166863DF Q34955918-CE15B495-4602-4878-8206-66AADCBD5890 Q35107308-A608AC80-C844-46EC-9E70-AD9A4952955F Q35662134-F86D1B89-98C8-40E8-927A-1D66DE31DE45 Q35744019-57EC13D1-42E0-49B6-A528-F9B00689E8B6 Q35925879-7467E7BD-262D-427E-B80B-2295D69E2CE7 Q36145170-14FFEA01-3644-4989-9058-558AFE428C8F Q36683297-991B6C9A-DEDD-4AD0-9AA6-4A06D7A008CD Q36847145-760C2143-6E88-4436-AD51-4DA41E18701B Q36972583-CB0EA8A7-A867-45B6-9343-F96B28510AC1 Q37508029-B6EDCD62-E7A2-429A-B906-71B3B9700238 Q37586952-218E357F-3C70-436E-8A67-81A3888D426F Q37766898-DB67CA5C-E285-4C04-A320-75D0BDCA97C5 Q38014901-1C0E1F2F-8CE0-4FE3-BEBB-AD6863FB1386 Q38132058-E67835D5-22E6-43F1-9285-FB08DA18A7C7 Q38164798-0FCE2706-BC90-4652-BC1B-6A8C7B9476A9 Q38265728-AD290353-0E0B-4AB8-9805-EDDBA7E82C38 Q38608749-9A484E07-5D37-41E1-B94E-390078C4A314 Q38979273-B939023F-72E4-4460-982E-2D47576C1852 Q41643121-5D68FD99-9D52-4D14-905F-58C44B752389 Q46739028-694CC480-F555-45D3-B5BB-8CB74E5E372D Q47134180-31807E53-D526-4E99-84E6-AE12B0E038B8 Q47614697-A9512A24-1C25-4E7E-A56D-6817FF604B20 Q51053022-6E18BA25-E56E-423E-B892-1893B3C7527D Q51334263-412E6CDB-5719-4E18-84D8-5003C366A7DB Q55360054-3042E590-8708-4F7F-B969-E0C857239615 Q57111615-4848FA6B-4D9B-436B-B525-DD73EBA91055 Q57112147-6756F9D1-2E94-48D2-994E-3A2967C8BEB6 Q57124605-CD709A99-C268-4CA8-A1CA-46F6339CD5D6 Q58568698-32A4EA43-8FBD-4BA4-8597-940FA1599259

P2860

Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR)

http://www.wikidata.org/entity/Q27653488

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Discovery of XL335 (WAY-362450 ...... the farnesoid X receptor (FXR)

@ast

Discovery of XL335 (WAY-362450 ...... the farnesoid X receptor (FXR)

@en

Discovery of XL335 (WAY-362450 ...... the farnesoid X receptor (FXR)

@nl

type

label

Discovery of XL335 (WAY-362450 ...... the farnesoid X receptor (FXR)

@ast

Discovery of XL335 (WAY-362450 ...... the farnesoid X receptor (FXR)

@en

Discovery of XL335 (WAY-362450 ...... the farnesoid X receptor (FXR)

@nl

prefLabel

Discovery of XL335 (WAY-362450 ...... the farnesoid X receptor (FXR)

@ast

Discovery of XL335 (WAY-362450 ...... the farnesoid X receptor (FXR)

@en

Discovery of XL335 (WAY-362450 ...... the farnesoid X receptor (FXR)

@nl

P1433

Q27653488-6E111B59-6D01-4252-94D6-240AF02BF616

P1476

Q27653488-CF288256-A57F-4E70-836C-6B7D0F846CE4

P2093

Q27653488-07268051-D714-478F-8D61-9B4AD1D13539

Q27653488-3B5923FF-3D5E-4155-961C-49A4DA17577A

Q27653488-4EE03C20-E648-4044-832A-494A3DBDC933

Q27653488-53760BE3-BCE5-4A0B-B02C-16FC53F31766

Q27653488-5E8DF88E-B44C-4FE1-AF05-12D63EA2353D

Q27653488-5F20AB39-D131-4056-B601-AA689FEF7650

Q27653488-64E0EBF1-F960-4F62-ADF2-8F987D97921C

Q27653488-6B895BF4-85D2-4D46-BD80-85D3027058D0

Q27653488-81D89ED8-C4CF-4059-B9D4-12AEF9D81D12

Q27653488-84873E2B-F4CE-4F82-87DE-0DB8CEF1D2DC

P304

Q27653488-5A4959DC-A95B-41E3-9DAE-B90BDC08A903

P31

Q27653488-55C4CA84-C788-42A4-BCDD-DBDF454CACB0

P3181

Q27653488-BD50B71A-D048-4C8F-B521-CFB3FF41EEAD

P356

Q27653488-997D0369-C79E-45E8-B443-C225DF532FC5

P407

Q27653488-A29B00E3-D7DF-4344-87BC-9E258C021202

P433

Q27653488-EDAF181C-9762-4B36-A6A1-14CCC400BAC3

P478

Q27653488-1FB70B89-ACB7-44C4-BCAD-7E4385F1B30B

P577

Q27653488-6E85AE7B-058A-4D50-B15C-A23C38854A8C

P698

Q27653488-17869710-7BC4-4801-BFC0-B110D6E06D76

P3181

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery of XL335 (WAY-362450 ...... the farnesoid X receptor (FXR)

@en

P2093

Brenton Flatt

http://www.w3.org/2001/XMLSchema#string

Brett Murphy

http://www.w3.org/2001/XMLSchema#string

Chris Daige

http://www.w3.org/2001/XMLSchema#string

Eric Bischoff

http://www.w3.org/2001/XMLSchema#string

Grace Yan

http://www.w3.org/2001/XMLSchema#string

Ira Schulman

http://www.w3.org/2001/XMLSchema#string

Jay Wrobel

http://www.w3.org/2001/XMLSchema#string

Jiali Li

http://www.w3.org/2001/XMLSchema#string

Mary Petrowski

http://www.w3.org/2001/XMLSchema#string

Paige Mahaney

http://www.w3.org/2001/XMLSchema#string

P304

904-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2409979

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/JM8014124

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19159286

http://www.w3.org/2001/XMLSchema#string